Daré Bioscience, Inc., a clinical-stage biopharmaceutical company, focuses on developing and marketing products for women's health in the United States. The company develops therapies in the areas of contraception, fertility, and sexual and vaginal health. Its products in advanced clinical development include DARE-BV1, a bioadhesive hydrogel formulated with clindamycin phosphate 2% to treat bacterial vaginosis in a single administration that has completed Phase 3 clinical trials; Ovaprene, a hormone-free monthly vaginal contraceptive; and Sildenafil Cream, a cream formulation of sildenafil for topical administration to the vulva and vagina for treatment of female sexual arousal disorder. The company's Phase 1-ready products are DARE-HRT1, a combination of bio-identical estradiol and progesterone intravaginal ring for the treatment of vasomotor symptoms in hormone therapy; DARE-VVA1, a vaginally delivered formulation of tamoxifen to treat vulvar vaginal atrophy in patients with hormone-receptor positive breast cancer; and DARE-FRT1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth and broader luteal phase support as part of an in vitro fertilization treatment plan. Its products in pre-clinical stage include DARE-LARC1, a combination product designed to provide reversible contraception; ORB-204 and ORB-214, an injectable formulations of etonogestrel to provide contraception over 6-month and 12-month periods; and DARE-RH1, a non-hormonal contraception for men and women. The company is headquartered in San Diego, California.
IPO Year: 2014
Exchange: NASDAQ
Website: darebioscience.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/30/2021 | $9.00 → $11.00 | Buy | Roth Capital |
Live FDA approvals issued by the Food and Drug Administration and FDA breaking news
Submission status for DARE BIOSCIENCE INC's drug XACIATO (ORIG-1) with active ingredient CLINDAMYCIN PHOSPHATE has changed to 'Approval' on 12/07/2021. Application Category: NDA, Application Number: 215650, Application Classification: Type 5 - New Formulation or New Manufacturer
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Roth Capital reiterated coverage of Dare Bioscience with a rating of Buy and set a new price target of $11.00 from $9.00 previously
Live finance-specific insights
DARE to PLAY™ Sildenafil Cream on Track for Q4 2025 Launch via 503B Compounding Pathway; Positioned for Product Revenue Beginning in Q4 2025 Positive Interim DSMB Outcome for Ovaprene® Phase 3 Study Supports Continued EnrollmentMultiple Grant-Funded Programs Advance, Including to Address HPV and Long-Acting ContraceptionFour Commercially Available Solutions for Women on the Horizon In addition to DARE to PLAY™ Sildenafil Cream, Commercialization of Vaginal Probiotics in the Consumer Health Market Targeted to follow DARE to PLAY Sildenafil Cream availability and Proprietary Monthly Hormone Therapy via 503B Compounding Pathway Targeted for Late 2026Creates Entry into the Estimated $4.5 Billi
SAN DIEGO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a biopharmaceutical company with a sole focus of closing the gap in women's health between promising science and real solutions, will host a conference call and live webcast at 4:30 p.m. Eastern Time on Thursday, August 14, 2025, to review its financial results for the quarter ended June 30, 2025 and to provide a company update. To access the conference call via phone, dial (646) 307-1963 or (800) 715-9871 (toll-free). The conference ID number for the call is 2684883. The live webcast can be accessed under "Presentations, Events & Webcasts" in the Investors section of the company's website at http://ir.d
Creates commercial opportunity in the estimated up to $4.5 billion compounded hormone therapy market, enabling women to access an evidence-based solutionFour on-market products will accelerate revenue generation and provide path to profitabilityDaré expects to start recording revenue in the 4th quarter of this year Conference call today at 4:30 p.m. ET to discuss the further expanded business strategy to commercialize multiple solutions in 2025 and 2026 2025 and 2026 Milestones Sildenafil Cream, 3.6% an investigational topical formulation of sildenafil being developed to treat female sexual arousal disorder, targeting availability via prescription as a Section 503B compounded drug t
SAN DIEGO, May 06, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a biopharmaceutical company driven by a mission to challenge the status quo, making women's health a priority, will host a conference call and live webcast at 4:30 p.m. Eastern Time on Tuesday, May 13, 2025, to review its financial results for the quarter ended March 31, 2025 and to provide a company update. To access the conference call via phone, dial (646) 307-1963 (U.S.) or (800) 715-9871 (toll-free). The conference ID number for the call is 3461324. The live webcast can be accessed under "Presentations, Events & Webcasts" in the Investors section of the company's website at http://ir.darebioscience.com.
Enables women to access a solution that they want and needCreates an opportunity to accelerate revenue generation from this proprietary formulation Daré expects to start recording revenue and cash flow in the 4th quarter of this year Conference call today at 4:30 p.m. ET to discuss the expanded business strategy to integrate 503B compounding as part of a dual-path approach to bring select Daré proprietary formulations to market as soon as practicable SAN DIEGO, March 31, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a biopharmaceutical company driven by a mission to challenge the status quo, making women's health a priority, today reported financial results for the year
SAN DIEGO, March 24, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in innovation for the health and well-being of women, will host a conference call and live webcast at 4:30 p.m. Eastern Time on Monday, March 31, 2025, to review its financial results for the year ended December 31, 2024, and to provide a company update. To access the conference call via phone, dial (646) 307-1963 (U.S.) or (800) 715-9871 (toll-free). The conference ID number for the call is 9767621. The live webcast can be accessed under "Presentations, Events & Webcasts" in the Investors section of the company's website at http://ir.darebioscience.com. Please log in approximate
Conference Call and Webcast Today at 4:30 p.m. ET Development Program Highlights and Anticipated Milestones Ovaprene® hormone-free monthly intravaginal contraceptive candidate – pivotal Phase 3 contraceptive efficacy study recruiting across the United States; foundation grant announced yesterday will provide funding to allow Daré to expand the number of clinical sites to accelerate the development timeline Sildenafil Cream, 3.6% topical formulation of sildenafil being developed to treat female sexual arousal disorder - continued operational progress toward a planned Phase 3 study, including constructive discussions with FDA; Phase 3 design, development, and collaboration strategy updates
SAN DIEGO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in innovation for the health and wellbeing of women, will host a conference call and live webcast at 4:30 p.m. Eastern Time on Thursday, November 14, 2024, to review its financial results for the quarter ended September 30, 2024 and to provide a company update. The company will release its financial results after the close of market on Thursday, November 14, 2024, and prior to the conference call and webcast. To access the conference call via phone, dial (646) 307-1963 (U.S.) or (800) 715-9871 (international). The conference ID number for the call is 6400145. The live webcast can be accessed under
Conference Call and Webcast Today at 4:30 p.m. ET Development Program Highlights and Anticipated 2024 Milestones Ovaprene® hormone-free monthly intravaginal contraceptive candidate pivotal Phase 3 contraceptive efficacy study recruiting across the United StatesSildenafil Cream, 3.6% topical formulation of sildenafil being developed to treat female sexual arousal disorder continued operational progress toward a planned Phase 3 study; additional FDA feedback forthcoming; Phase 3 design, development, and collaboration strategy updates SAN DIEGO, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in innovation for the health and wellbeing of women, today reporte
SAN DIEGO, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in innovation for the health and wellbeing of women, will host a conference call and live webcast at 4:30 p.m. Eastern Time on Monday, August 12, 2024, to review its financial results for the quarter ended June 30, 2024 and to provide a company update. The company will release its financial results after the close of market on Monday, August 12, 2024, and prior to the conference call and webcast. To access the conference call via phone, dial (646) 307-1952 (U.S.) or (888) 672-2415 (international). The conference ID number for the call is 6756565. The live webcast can be accessed under "Presentation
This live feed shows all institutional transactions in real time.
SC 13G/A - Dare Bioscience, Inc. (0001401914) (Subject)
SC 13G/A - Dare Bioscience, Inc. (0001401914) (Subject)
SC 13G/A - Dare Bioscience, Inc. (0001401914) (Subject)
SC 13G - Dare Bioscience, Inc. (0001401914) (Subject)
SC 13G/A - Dare Bioscience, Inc. (0001401914) (Subject)
SC 13G - Dare Bioscience, Inc. (0001401914) (Subject)
Fastest customizable press release news feed in the world
DARE to PLAY™ Sildenafil Cream on Track for Q4 2025 Launch via 503B Compounding Pathway; Positioned for Product Revenue Beginning in Q4 2025 Positive Interim DSMB Outcome for Ovaprene® Phase 3 Study Supports Continued EnrollmentMultiple Grant-Funded Programs Advance, Including to Address HPV and Long-Acting ContraceptionFour Commercially Available Solutions for Women on the Horizon In addition to DARE to PLAY™ Sildenafil Cream, Commercialization of Vaginal Probiotics in the Consumer Health Market Targeted to follow DARE to PLAY Sildenafil Cream availability and Proprietary Monthly Hormone Therapy via 503B Compounding Pathway Targeted for Late 2026Creates Entry into the Estimated $4.5 Billi
SAN DIEGO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a biopharmaceutical company with a sole focus of closing the gap in women's health between promising science and real solutions, will host a conference call and live webcast at 4:30 p.m. Eastern Time on Thursday, August 14, 2025, to review its financial results for the quarter ended June 30, 2025 and to provide a company update. To access the conference call via phone, dial (646) 307-1963 or (800) 715-9871 (toll-free). The conference ID number for the call is 2684883. The live webcast can be accessed under "Presentations, Events & Webcasts" in the Investors section of the company's website at http://ir.d
A first-of-its-kind solution for women's arousal in a proprietary topical formulation demonstrated to work where women need it most Targeted to be available by prescription in the fourth quarter of 2025 Collaboration leverages Rosy Wellness' extensive reach and community of over 250,000 women; campaign designed to drive awareness and support women with arousal concerns SAN DIEGO, July 29, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a biopharmaceutical company with a sole focus of closing the gap in women's health between promising science and real solutions, and Rosy Wellness, a pioneering digital platform focused on providing lifespan support for women, today announce
A first-of-its-kind solution for women's arousal - the same active ingredient as in Viagra® for men - in a proprietary topical formulation demonstrated to work where women need it most Targeted to be available by prescription in the fourth quarter of 2025 SAN DIEGO, July 21, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a biopharmaceutical company with a sole focus of closing the gap in women's health between promising science and real solutions, today announced a live webinar on Wednesday, August 6, 2025, unveiling the DARE to PLAY™ difference - a groundbreaking solution for female sexual arousal with the first and only evidence-backed sildenafil cream formulation for wo
A first-of-its-kind solution for women's arousal - the same active ingredient as in Viagra® for men - in a proprietary topical formulation demonstrated to work where women need it most Targeted to be available by prescription in the fourth quarter of 2025 SAN DIEGO, July 21, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a biopharmaceutical company with a sole focus of closing the gap in women's health between promising science and real solutions, today announced a live webinar on Wednesday, August 6, 2025, unveiling the DARE to PLAY™ difference - a groundbreaking solution for female sexual arousal with the first and only evidence-backed sildenafil cream formulation for wo
SAN DIEGO, July 14, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a biopharmaceutical company driven by a mission to challenge the status quo, making women's health a priority, today announced positive interim safety and efficacy results from its ongoing Phase 3 clinical trial evaluating the contraceptive effectiveness, safety and acceptability of Ovaprene®, the company's investigational monthly, hormone-free intravaginal contraceptive. There currently are no FDA-approved, hormone-free, monthly intravaginal contraceptives. The trial's independent Data Safety Monitoring Board (DSMB) conducted a planned interim analysis focused on reviewing safety data from the study, and re
SAN DIEGO, July 11, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a biopharmaceutical company driven by a mission to challenge the status quo, making women's health a priority, today announced the receipt of a $6 million non-dilutive funding installment under its multi-year grant agreement to support development of DARE-LARC1, the contraception-focused use case of Daré's intelligent drug delivery system (DARE-IDDS) platform. This brings the total received to approximately $37.8 million of up to approximately $49 million in committed grant funding for nonclinical development, IND-enabling studies, and preparation for submission of an Investigational New Drug (IND) applicati
SAN DIEGO, June 12, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a biopharmaceutical company driven by a mission to challenge the status quo, making women's health a priority, today announced that the company's 2025 annual meeting of stockholders (the "Annual Meeting") was convened and adjourned without any business conducted due to lack of the required quorum. A quorum is necessary to hold the Annual Meeting. There were fewer than a majority of shares entitled to vote present, either in person or by proxy, at the Annual Meeting. The Annual Meeting therefore had no quorum and was adjourned to allow time to solicit additional proxies on behalf of the company's board of
Collaboration will leverage Rosy Wellness' extensive reach and community of over 250,000 women Rosy Wellness is a multi-award winning app recommended by 8,000+ healthcare professionals Daré expects to start recording revenue in the 4th quarter this year SAN DIEGO, June 04, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a biopharmaceutical company driven by a mission to challenge the status quo, making women's health a priority, and Rosy Wellness, a pioneering digital platform focused on providing lifespan support for women, today announced a strategic collaboration to support the upcoming marketing and consumer and healthcare provider awareness campaign for Daré's DARE t
Creates commercial opportunity in the estimated up to $4.5 billion compounded hormone therapy market, enabling women to access an evidence-based solutionFour on-market products will accelerate revenue generation and provide path to profitabilityDaré expects to start recording revenue in the 4th quarter of this year Conference call today at 4:30 p.m. ET to discuss the further expanded business strategy to commercialize multiple solutions in 2025 and 2026 2025 and 2026 Milestones Sildenafil Cream, 3.6% an investigational topical formulation of sildenafil being developed to treat female sexual arousal disorder, targeting availability via prescription as a Section 503B compounded drug t
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - Dare Bioscience, Inc. (0001401914) (Issuer)
4 - Dare Bioscience, Inc. (0001401914) (Issuer)
4 - Dare Bioscience, Inc. (0001401914) (Issuer)
4 - Dare Bioscience, Inc. (0001401914) (Issuer)
4 - Dare Bioscience, Inc. (0001401914) (Issuer)
4 - Dare Bioscience, Inc. (0001401914) (Issuer)
4 - Dare Bioscience, Inc. (0001401914) (Issuer)
4 - Dare Bioscience, Inc. (0001401914) (Issuer)
4 - Dare Bioscience, Inc. (0001401914) (Issuer)
4 - Dare Bioscience, Inc. (0001401914) (Issuer)
10-Q - Dare Bioscience, Inc. (0001401914) (Filer)
8-K - Dare Bioscience, Inc. (0001401914) (Filer)
8-K - Dare Bioscience, Inc. (0001401914) (Filer)
8-K - Dare Bioscience, Inc. (0001401914) (Filer)
8-K - Dare Bioscience, Inc. (0001401914) (Filer)
8-K - Dare Bioscience, Inc. (0001401914) (Filer)
DEFA14A - Dare Bioscience, Inc. (0001401914) (Filer)
8-K - Dare Bioscience, Inc. (0001401914) (Filer)
10-Q - Dare Bioscience, Inc. (0001401914) (Filer)
8-K - Dare Bioscience, Inc. (0001401914) (Filer)
Live Leadership Updates
A first-of-its-kind solution for women's arousal in a proprietary topical formulation demonstrated to work where women need it most Targeted to be available by prescription in the fourth quarter of 2025 Collaboration leverages Rosy Wellness' extensive reach and community of over 250,000 women; campaign designed to drive awareness and support women with arousal concerns SAN DIEGO, July 29, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a biopharmaceutical company with a sole focus of closing the gap in women's health between promising science and real solutions, and Rosy Wellness, a pioneering digital platform focused on providing lifespan support for women, today announce
SAN DIEGO, Jan. 26, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women's health innovation, today announced changes in company management which includes the retirement of Chief Financial Officer, Lisa Walters-Hoffert, and the resignation of Chief Commercial Officer, John Fair. Both Ms. Walters-Hoffert and Mr. Fair have entered into plans with the Company to help ensure a seamless transition. Daré also announced an adjustment to the size of its Board of Directors to better reflect the Company's size following the voluntary resignations of Cheryl R. Blanchard, Ph.D. and Sophia Ononye-Onyia, Ph.D. "On behalf of the Daré team, I am so grateful to Lisa and Joh
SAN DIEGO, April 19, 2021 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women's health innovation, today announced the appointment of Sophia N. Ononye-Onyia, PhD MPH MBA to its Board of Directors. "We are thrilled to add Dr. Ononye-Onyia to the Daré Board," said Sabrina Martucci Johnson, Daré's President and CEO. "Sophia has demonstrated the value of her leadership to global biopharmaceutical companies throughout her career. Her experience supporting commercialization of women's health products positions her to provide strategic guidance as our product candidates advance toward commercialization, and as we explore the variety of go-to-market partnering strategies